Gastrointestinal Stromal Tumor Market - A Global and Regional Analysis: Focus on Country and Region - Analysis and Forecast, 2025-2035
A Gastrointestinal stromal tumor (GIST) is a type of cancer that originates in the cells of the gastrointestinal (GI) tract, most commonly in the stomach or small intestine. GISTs arise from the interstitial cells of Cajal (ICC), which are part of the GI tract’s nervous system, responsible for controlling muscle contractions. These tumors can be benign or malignant, with the majority being malignant and capable of spreading to other organs. GISTs are often characterized by their unique mutations, most notably in the KIT gene or PDGFRA gene, which play a role in cell growth. Symptoms of GISTs can vary, with some patients being asymptomatic, while others may experience abdominal pain, bleeding, or obstruction. Diagnosis typically involves imaging techniques like CT scans or endoscopy, alongside biopsy for confirmation.
The growing global incidence of GISTs is a major factor driving market growth. While GISTs are relatively rare, the incidence of these tumors has been steadily increasing, likely due to improvements in diagnostic techniques and increased awareness. As more cases are diagnosed, there is a higher demand for targeted therapies, surgical interventions, and long-term management options. The rising number of GIST cases is pushing healthcare providers and pharmaceutical companies to focus more on developing effective treatments, thus expanding the market.
Additionally, Advancements in precision oncology and targeted therapies are revolutionizing the treatment landscape for GISTs. Targeted therapies, particularly tyrosine kinase inhibitors like imatinib, have become a standard treatment for advanced or metastatic GISTs. These therapies work by specifically targeting the molecular mutations that drive GISTs, offering patients more effective and less toxic treatment options compared to traditional chemotherapy. Additionally, the rise of personalized medicine, where treatments are tailored based on the genetic makeup of both the patient and the tumor, is providing significant opportunities for more effective and individualized GIST management. As precision oncology continues to evolve, it is expected to lead to better patient outcomes and, consequently, further growth in the GIST market.
However, despite the promising growth of the gastrointestinal stromal tumor market, several challenges exist. One of the significant barriers to market growth is the high cost of treatment for GISTs, particularly for targeted therapies such as tyrosine kinase inhibitors. These therapies are essential for managing advanced or metastatic gastrointestinal stromal tumors are often expensive, making them less accessible to patients in low- and middle-income countries. The cost of long-term treatment and monitoring can also burden healthcare systems, limiting patient access to necessary therapies and impacting the overall market adoption. Adding to this, the absence of curative therapies for recurrent or metastatic GISTs is a significant limitation, as patients may require long-term, continuous treatment without achieving complete remission. This gap in curative options hinders market growth as patients may face limitations in treatment success.
The global gastrointestinal stromal tumor market is highly competitive, with several leading companies driving innovation and market growth, such as Arog Pharmaceuticals, Cogent Biosciences, Inc., Bayer AG, Novartis AG, and Pfizer Inc. To expand their presence in the gastrointestinal stromal tumor market, companies are pursuing several strategic initiatives. Companies in the Gastrointestinal Stromal Tumor (GIST) market have adopted several strategic initiatives to expand their presence and drive growth. One of the key strategies is investment in research and development to advance the understanding of GISTs at the molecular level and discover novel therapies, particularly targeted treatments that can address drug resistance and improve long-term outcomes. Collaborations between pharmaceutical companies and academic institutions are also becoming more common, enabling the pooling of resources and expertise to accelerate drug discovery and clinical trials.
Market Segmentation:
Segmentation 1: by Region
Hard copy option is available on any of the options above at an additional charge of $500. Please email us at [email protected] with your request.
This report will be delivered in 2 working days.
The growing global incidence of GISTs is a major factor driving market growth. While GISTs are relatively rare, the incidence of these tumors has been steadily increasing, likely due to improvements in diagnostic techniques and increased awareness. As more cases are diagnosed, there is a higher demand for targeted therapies, surgical interventions, and long-term management options. The rising number of GIST cases is pushing healthcare providers and pharmaceutical companies to focus more on developing effective treatments, thus expanding the market.
Additionally, Advancements in precision oncology and targeted therapies are revolutionizing the treatment landscape for GISTs. Targeted therapies, particularly tyrosine kinase inhibitors like imatinib, have become a standard treatment for advanced or metastatic GISTs. These therapies work by specifically targeting the molecular mutations that drive GISTs, offering patients more effective and less toxic treatment options compared to traditional chemotherapy. Additionally, the rise of personalized medicine, where treatments are tailored based on the genetic makeup of both the patient and the tumor, is providing significant opportunities for more effective and individualized GIST management. As precision oncology continues to evolve, it is expected to lead to better patient outcomes and, consequently, further growth in the GIST market.
However, despite the promising growth of the gastrointestinal stromal tumor market, several challenges exist. One of the significant barriers to market growth is the high cost of treatment for GISTs, particularly for targeted therapies such as tyrosine kinase inhibitors. These therapies are essential for managing advanced or metastatic gastrointestinal stromal tumors are often expensive, making them less accessible to patients in low- and middle-income countries. The cost of long-term treatment and monitoring can also burden healthcare systems, limiting patient access to necessary therapies and impacting the overall market adoption. Adding to this, the absence of curative therapies for recurrent or metastatic GISTs is a significant limitation, as patients may require long-term, continuous treatment without achieving complete remission. This gap in curative options hinders market growth as patients may face limitations in treatment success.
The global gastrointestinal stromal tumor market is highly competitive, with several leading companies driving innovation and market growth, such as Arog Pharmaceuticals, Cogent Biosciences, Inc., Bayer AG, Novartis AG, and Pfizer Inc. To expand their presence in the gastrointestinal stromal tumor market, companies are pursuing several strategic initiatives. Companies in the Gastrointestinal Stromal Tumor (GIST) market have adopted several strategic initiatives to expand their presence and drive growth. One of the key strategies is investment in research and development to advance the understanding of GISTs at the molecular level and discover novel therapies, particularly targeted treatments that can address drug resistance and improve long-term outcomes. Collaborations between pharmaceutical companies and academic institutions are also becoming more common, enabling the pooling of resources and expertise to accelerate drug discovery and clinical trials.
Market Segmentation:
Segmentation 1: by Region
- North America
- Europe
- Asia-Pacific
Hard copy option is available on any of the options above at an additional charge of $500. Please email us at [email protected] with your request.
This report will be delivered in 2 working days.
Executive Summary
Scope and Definition
Market/Product Definition
Inclusion and Exclusion
Key Questions Answered
Analysis and Forecast Note
1. GLOBAL GASTROINTESTINAL STROMAL TUMOR MARKET: INDUSTRY ANALYSIS
1.1 Market Overview and Ecosystem
1.2 Epidemiological Analysis
1.3 Key Market Trends
1.3.1 Impact Analysis
1.4 Regulatory Landscape
1.5 Pipeline Analysis
1.6 Market Dynamics
1.6.1 Overview
1.6.2 Market Drivers
1.6.3 Market Restraints
1.6.4 Market Opportunities
2. GLOBAL GASTROINTESTINAL STROMAL TUMOR MARKET (BY REGION), VALUE ($MILLION), 2024-2035
2.1 North America
2.1.1 Market Dynamics
2.1.2 Market Sizing and Forecast
2.1.3 North America Gastrointestinal Stromal Tumor Market, by Country ($Million), 2024-2035
2.1.3.1 U.S.
2.2 Europe
2.2.1 Market Dynamics
2.2.2 Market Sizing and Forecast
2.2.3 Europe Gastrointestinal Stromal Tumor Market, by Country ($Million), 2024-2035
2.2.3.1 U.K.
2.2.3.2 France
2.2.3.3 Germany
2.2.3.4 Italy
2.2.3.5 Spain
2.3 Asia-Pacific
2.3.1 Market Dynamics
2.3.2 Market Sizing and Forecast
2.3.3 Asia-Pacific Gastrointestinal Stromal Tumor Market, by Country ($Million), 2024-2035
2.3.3.1 Japan
3. COMPETITIVE LANDSCAPE AND COMPANY PROFILES
3.1 Competitive Landscape
3.1.1 Mergers and Acquisitions
3.1.2 Partnership, Alliances and Business Expansion
3.1.3 New Offerings
3.1.4 Regulatory Activities
3.1.5 Funding Activities
3.2 Company Profiles
3.2.1 Arog Pharmaceuticals.
3.2.1.1 Overview
3.2.1.2 Top Products / Product Portfolio
3.2.1.3 Top Competitors
3.2.1.4 Target Customers/End-Users
3.2.1.5 Key Personnel
3.2.1.6 Analyst View
3.2.2 Cogent Biosciences, Inc.
3.2.2.1 Overview
3.2.2.2 Top Products / Product Portfolio
3.2.2.3 Top Competitors
3.2.2.4 Target Customers/End-Users
3.2.2.5 Key Personnel
3.2.2.6 Analyst View
3.2.3 Blueprint Medicines Corporation.
3.2.3.1 Overview
3.2.3.2 Top Products / Product Portfolio
3.2.3.3 Top Competitors
3.2.3.4 Target Customers/End-Users
3.2.3.5 Key Personnel
3.2.3.6 Analyst View
3.2.4 Abeona Therapeutics.
3.2.4.1 Overview
3.2.4.2 Top Products / Product Portfolio
3.2.4.3 Top Competitors
3.2.4.4 Target Customers/End-Users
3.2.4.5 Key Personnel
3.2.4.6 Analyst View
3.2.5 Bayer AG.
3.2.5.1 Overview
3.2.5.2 Top Products / Product Portfolio
3.2.5.3 Top Competitors
3.2.5.4 Target Customers/End-Users
3.2.5.5 Key Personnel
3.2.5.6 Analyst View
3.2.6 Novartis AG.
3.2.6.1 Overview
3.2.6.2 Top Products / Product Portfolio
3.2.6.3 Top Competitors
3.2.6.4 Target Customers/End-Users
3.2.6.5 Key Personnel
3.2.6.6 Analyst View
3.2.7 Deciphera Pharmaceuticals.
3.2.7.1 Overview
3.2.7.2 Top Products / Product Portfolio
3.2.7.3 Top Competitors
3.2.7.4 Target Customers/End-Users
3.2.7.5 Key Personnel
3.2.7.6 Analyst View
3.2.8 Pfizer Inc.
3.2.8.1 Overview
3.2.8.2 Top Products / Product Portfolio
3.2.8.3 Top Competitors
3.2.8.4 Target Customers/End-Users
3.2.8.5 Key Personnel
3.2.8.6 Analyst View
3.2.9 Hoffmann-La Roche (Genentech).
3.2.9.1 Overview
3.2.9.2 Top Products / Product Portfolio
3.2.9.3 Top Competitors
3.2.9.4 Target Customers/End-Users
3.2.9.5 Key Personnel
3.2.9.6 Analyst View
3.2.10 Taiho Pharmaceutical.
3.2.10.1 Overview
3.2.10.2 Top Products / Product Portfolio
3.2.10.3 Top Competitors
3.2.10.4 Target Customers/End-Users
3.2.10.5 Key Personnel
3.2.10.6 Analyst View
3.2.11 Others
4. RESEARCH METHODOLOGY
Scope and Definition
Market/Product Definition
Inclusion and Exclusion
Key Questions Answered
Analysis and Forecast Note
1. GLOBAL GASTROINTESTINAL STROMAL TUMOR MARKET: INDUSTRY ANALYSIS
1.1 Market Overview and Ecosystem
1.2 Epidemiological Analysis
1.3 Key Market Trends
1.3.1 Impact Analysis
1.4 Regulatory Landscape
1.5 Pipeline Analysis
1.6 Market Dynamics
1.6.1 Overview
1.6.2 Market Drivers
1.6.3 Market Restraints
1.6.4 Market Opportunities
2. GLOBAL GASTROINTESTINAL STROMAL TUMOR MARKET (BY REGION), VALUE ($MILLION), 2024-2035
2.1 North America
2.1.1 Market Dynamics
2.1.2 Market Sizing and Forecast
2.1.3 North America Gastrointestinal Stromal Tumor Market, by Country ($Million), 2024-2035
2.1.3.1 U.S.
2.2 Europe
2.2.1 Market Dynamics
2.2.2 Market Sizing and Forecast
2.2.3 Europe Gastrointestinal Stromal Tumor Market, by Country ($Million), 2024-2035
2.2.3.1 U.K.
2.2.3.2 France
2.2.3.3 Germany
2.2.3.4 Italy
2.2.3.5 Spain
2.3 Asia-Pacific
2.3.1 Market Dynamics
2.3.2 Market Sizing and Forecast
2.3.3 Asia-Pacific Gastrointestinal Stromal Tumor Market, by Country ($Million), 2024-2035
2.3.3.1 Japan
3. COMPETITIVE LANDSCAPE AND COMPANY PROFILES
3.1 Competitive Landscape
3.1.1 Mergers and Acquisitions
3.1.2 Partnership, Alliances and Business Expansion
3.1.3 New Offerings
3.1.4 Regulatory Activities
3.1.5 Funding Activities
3.2 Company Profiles
3.2.1 Arog Pharmaceuticals.
3.2.1.1 Overview
3.2.1.2 Top Products / Product Portfolio
3.2.1.3 Top Competitors
3.2.1.4 Target Customers/End-Users
3.2.1.5 Key Personnel
3.2.1.6 Analyst View
3.2.2 Cogent Biosciences, Inc.
3.2.2.1 Overview
3.2.2.2 Top Products / Product Portfolio
3.2.2.3 Top Competitors
3.2.2.4 Target Customers/End-Users
3.2.2.5 Key Personnel
3.2.2.6 Analyst View
3.2.3 Blueprint Medicines Corporation.
3.2.3.1 Overview
3.2.3.2 Top Products / Product Portfolio
3.2.3.3 Top Competitors
3.2.3.4 Target Customers/End-Users
3.2.3.5 Key Personnel
3.2.3.6 Analyst View
3.2.4 Abeona Therapeutics.
3.2.4.1 Overview
3.2.4.2 Top Products / Product Portfolio
3.2.4.3 Top Competitors
3.2.4.4 Target Customers/End-Users
3.2.4.5 Key Personnel
3.2.4.6 Analyst View
3.2.5 Bayer AG.
3.2.5.1 Overview
3.2.5.2 Top Products / Product Portfolio
3.2.5.3 Top Competitors
3.2.5.4 Target Customers/End-Users
3.2.5.5 Key Personnel
3.2.5.6 Analyst View
3.2.6 Novartis AG.
3.2.6.1 Overview
3.2.6.2 Top Products / Product Portfolio
3.2.6.3 Top Competitors
3.2.6.4 Target Customers/End-Users
3.2.6.5 Key Personnel
3.2.6.6 Analyst View
3.2.7 Deciphera Pharmaceuticals.
3.2.7.1 Overview
3.2.7.2 Top Products / Product Portfolio
3.2.7.3 Top Competitors
3.2.7.4 Target Customers/End-Users
3.2.7.5 Key Personnel
3.2.7.6 Analyst View
3.2.8 Pfizer Inc.
3.2.8.1 Overview
3.2.8.2 Top Products / Product Portfolio
3.2.8.3 Top Competitors
3.2.8.4 Target Customers/End-Users
3.2.8.5 Key Personnel
3.2.8.6 Analyst View
3.2.9 Hoffmann-La Roche (Genentech).
3.2.9.1 Overview
3.2.9.2 Top Products / Product Portfolio
3.2.9.3 Top Competitors
3.2.9.4 Target Customers/End-Users
3.2.9.5 Key Personnel
3.2.9.6 Analyst View
3.2.10 Taiho Pharmaceutical.
3.2.10.1 Overview
3.2.10.2 Top Products / Product Portfolio
3.2.10.3 Top Competitors
3.2.10.4 Target Customers/End-Users
3.2.10.5 Key Personnel
3.2.10.6 Analyst View
3.2.11 Others
4. RESEARCH METHODOLOGY
LIST OF FIGURES
Figure: Gastrointestinal Stromal Tumor Market (by Scenario), $Million, 2024, 2030, and 2035
Figure: Global Gastrointestinal Stromal Tumor Market, 2024 and 2035
Figure: Global Gastrointestinal Stromal Tumor Market Key Trends, Impact Analysis
Figure: North America Gastrointestinal Stromal Tumor Market, $Million, 2024-2035
Figure: Europe Gastrointestinal Stromal Tumor Market, $Million, 2024-2035
Figure: Asia-Pacific Gastrointestinal Stromal Tumor Market, $Million, 2024-2035
Figure: Gastrointestinal Stromal Tumor Market (by Scenario), $Million, 2024, 2030, and 2035
Figure: Global Gastrointestinal Stromal Tumor Market, 2024 and 2035
Figure: Global Gastrointestinal Stromal Tumor Market Key Trends, Impact Analysis
Figure: North America Gastrointestinal Stromal Tumor Market, $Million, 2024-2035
Figure: Europe Gastrointestinal Stromal Tumor Market, $Million, 2024-2035
Figure: Asia-Pacific Gastrointestinal Stromal Tumor Market, $Million, 2024-2035
LIST OF TABLES
Table: Market Snapshot
Table: Market Dynamics
Table: Global Gastrointestinal Stromal Tumor Market (by Region), $Million, 2024-2035
Table: Market Snapshot
Table: Market Dynamics
Table: Global Gastrointestinal Stromal Tumor Market (by Region), $Million, 2024-2035
